Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer

Pediatric Blood and Cancer

Volumn 47, Issue 5, 2006, Pages 567-571

  Pinarli, F G ^a   Elli, M ^a   Dagdemir A ^a   Baysal, K ^a   Acar, S ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

Cancer; Children; Electrocardiography; Serotonin antagonists

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CISPLATIN; CYTOTOXIC AGENT; GRANISETRON; ONDANSETRON; SEROTONIN 3 ANTAGONIST; ANTIEMETIC AGENT; SEROTONIN 3 RECEPTOR; SEROTONIN ANTAGONIST;

ADOLESCENT; ADULT; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CHILDHOOD CANCER; CLINICAL ARTICLE; DRUG EFFICACY; DRUG INFUSION; ECG ABNORMALITY; FEMALE; HEART ARRHYTHMIA; HEART RATE; HEART RHYTHM; HUMAN; MALE; PR INTERVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; QRS COMPLEX; QT DISPERSION; QT INTERVAL; QT PROLONGATION; SCHOOL CHILD; ST SEGMENT; CHEMICALLY INDUCED DISORDER; CHILD; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; ELECTROCARDIOGRAPHY; NAUSEA; NEOPLASM; PREDICTION AND FORECASTING; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; ELECTROCARDIOGRAPHY; FEMALE; GRANISETRON; HEART RATE; HUMANS; MALE; NAUSEA; NEOPLASMS; ONDANSETRON; PREDICTIVE VALUE OF TESTS; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 33748490073     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20639     Document Type: Article

References (30)

1. Seynaeve C, Verweij J, de Mulder PH. 5-HT3 receptor antagonists, a new approach in emesis: A review of ondansetron, granisetron, and tropisetron. Anticancer Drugs 1991;2:343-355.
2. Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother 2003;37:1276-1286.
3. Buyukavci M, Olgun H, Ceviz N. The effects of Ondansetron and Granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. Am J Clin Oncol 2005;28:201-204.
4. 3 receptor antagonist antiemetics: Is there cause for concern? Oncologist 2002;7:65-72.
5. Wortman JE, Lucas VS, Jr., Pharm BS, et al. Sudden death during doxorubicin administration. Cancer 1979;44:1588-1591.
6. Massin MM, Dresse MF, Schmitz V, et al. Acute arrhythmogenicity of first-dose chemotherapeutic agents in children. Med Pediatr Oncol 2002;39:93-98.
7. O'Bryan RM, Luce JK, Talley RW, et al. Phase II evaluation of adriamycin in human neoplasia. Cancer 1973;32:1-8.
8. Menard O, Martinet Y, Lamy P. Cisplatin-induced atrial fibrillation. J Clin Oncol 1991;9:192-193.
9. Boike SC, Ilson B, Zariffa N, et al. Cardiovascular effects of i.v. granisetron at two administration rates and of ondansetron in healthy adults. Am J Health Syst Pharm 1997;54:1172-1176.
10. Vloka ME, Steinberg JS. QT dispersion: Current and future clinical role. J Invasive Cardiol 1996;8:363-369.
11. Day CP, McComb JM, Campbell RW. QT dispersion: An indication of arrhythmia risk in patients with long QT intervals. Br Heart J 1990;63:342-344.
12. Suys BE, Huybrechts SJ, De Wolf D, et al. QTc interval prolongation and QTc dispersion in children and adolescents with type 1 diabetes. J Pediatr 2002;141:59-63.
13. 3 receptor channel. Annu Rev Physiol 1995;57:447-468.
14. Saxena PR, Villalon CM. 5-Hydroxytryptamine: A chameleon in the heart. Trends Pharmacol Sci 1991;12:223-227.
15. Baguley WA, Hay WT, Mackie KP, et al. Cardiac dysrhythmias associated with the intravenous administration of ondansetron and metoclopramide. Anesth Analg 1997;84:1380-1381.
16. Benedict CR, Arbogast R, Martin L, et al. Single-blind study of the effects of intravenous dolasetron mesylate versus ondansetron on electrocardiographic parameters in normal volunteers. J Cardiovasc Pharmacol 1996;28:53-59.
17. Jantunen IT, Kataja VV, Muhonen TT, et al. Effects of granisetron with doxorubicin or epirubicin on ECG intervals. Cancer Chemother Pharmacol 1996;37:502-504.
18. Watanabe H, Hasegawa A, Shinozaki T, et al. Possible cardiac side effects of granisetron, an antiemetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy. Cancer Chemother Pharmacol 1995;35:278-282.
19. Aapro M, Bourke JP. Rapid intravenous administration of granisetron prior to chemotherapy is not arythmogenic: Results of a pilot study. Eur J Cancer 2003;39:927-931.
20. Carmichael J, Philip PA, Forfar C, et al. An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease. Cancer Chemother Pharmacol 1995;37:134-138.
21. Baltzer L, Kris MG, Hinkley L, et al. Reversible electrocardiograhic interval prolongations following the specific serotonin antagonists ondansetron and dolasetron mesylate: A possible drug class effect without sequelae? Proc Am Soc Clin Oncol 1994;13:433a.
22. Lofters WS, Pater JL, Zee B, et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 1997;15:2966-2973.
23. Nousiainen T, Vanninen E, Rantala A, et al. QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin lymphoma. J Intern Med 1999;245:359-364.
24. Larsen RL, Jakacki RI, Vetter VL, et al. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 1992;70:73-77.
25. Steinberg JS, Cohen AJ, Wasserman AG, et al. Acute arrhytmogenicity of doxorubicin administration. Cancer 1987;60:1213-1218.
26. Bender KS, Shematek JP, Leventhal BG, et al. QT interval prolongation associated with anthracycline cardiotoxicity. J Pediatr 1984;105:442-444.
27. Schwartz CL, Hobbie WL, Truesdell S, et al. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol 1993;11:1906-1910.
28. Gupta M, Thaler HT, Steinherz L. Presence of prolonged dispersion of QT intervals in late survivors of childhood anthracycline therapy. Pediatr Hematol Oncol 2002;19:533-542.
29. Coppes MJ, Lau R, Ingram LC, et al. Open-label comparison of the antiemetic efficacy of single intravenous doses of Dolasetron Mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. Med Ped Oncol 1999;33:99-105.
30. Coppes MJ, Yanofsky R, Pritchard S, et al. Safety, tolerability, antiemetic efficacy, and pharmacokinetics of oral dolasetron mesylate in pediatric cancer patients receiving moderately to highly emetogenic chemotherapy. J Pediatr Hematol Oncol 1999;21:274-283.